Rheumocam 1mg and 2.5mg Tablets Species: Dogs Therapeutic indication: Pharmaceuticals: Anti-inflammatory preparations: Oral: Other NSAIDs Active ingredient: Meloxicam Product:Rheumocam 1mg and 2.5mg Chewable Tablets Product index: Rheumocam Chewable Tablets Presentation Pale-yellow, single-scored, pork flavoured chewable tablets containing 1mg or 2.5mg meloxicam. Uses Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Dosage and administration Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively. Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. Rheumocam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily. The use of Rheumocam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Rheumocam oral suspension for dogs is recommended. A clinical response is normally seen within 3 – 4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent. Contra-indications, warnings, etc Do not use in pregnant or lactating animals. Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in dogs less than 6 weeks of age or less than 4 kg body weight. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Adverse reactions Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. Precautions for use in animals Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. User warnings People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician. Interactions Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously. Overdose In the case of overdosage symptomatic treatment should be initiated. Pharmaceutical precautions This veterinary medicinal product does not require any special storage conditions Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Legal category Legal category: POM-V